WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317326

CAS#: 155206-00-1

Description: Bimatoprost, also known as AGN 192024, is a potent FP receptor agonist. Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.

Chemical Structure

CAS# 155206-00-1

Theoretical Analysis

MedKoo Cat#: 317326
Name: Bimatoprost
CAS#: 155206-00-1
Chemical Formula: C25H37NO4
Exact Mass: 415.27226
Molecular Weight: 415.57
Elemental Analysis: C, 72.26; H, 8.97; N, 3.37; O, 15.40

Price and Availability

Size Price Availability Quantity
10.0mg USD 90.0 Same day
25.0mg USD 150.0 Same day
50.0mg USD 250.0 Same day
100.0mg USD 450.0 Same day
200.0mg USD 750.0 Same day
500.0mg USD 1450.0 Same day
1.0g USD 2250.0 Same day
2.0g USD 3450.0 Same day
5.0g USD 5450.0 2 weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: AGN 192024; AGN192024; AGN-192024; Bimatoprost; Lumigan; Latisse; Bimatoprostum; Lumigan.

IUPAC/Chemical Name: (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide


InChi Code: InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3+,17-16+


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 415.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Padhy D, Rao A. Bimatoprost (0.03%)-induced accommodative spasm and
pseudomyopia. BMJ Case Rep. 2015 Nov 23;2015. pii: bcr2015211820. doi:
10.1136/bcr-2015-211820. PubMed PMID: 26598527.

2: Oddone F, Rossetti L, Tanga L, Berardo F, Ferrazza M, Michelessi M, Roberti G,
Manni G, Centofanti M. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on
Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or
Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical
Trial. PLoS One. 2015 Oct 20;10(10):e0140601. doi: 10.1371/journal.pone.0140601.
eCollection 2015. PubMed PMID: 26484767; PubMed Central PMCID: PMC4615626.

3: Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E,
Krauss AH. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric
Oxide-Donating Bimatoprost in Preclinical Models. Invest Ophthalmol Vis Sci. 2015
Oct 1;56(11):6558-64. doi: 10.1167/iovs.15-17190. PubMed PMID: 26457541.

4: Karslioğlu MZ, Hoşal MB, Tekeli O. Periocular changes in topical bimatoprost
and latanoprost use. Turk J Med Sci. 2015;45(4):925-30. PubMed PMID: 26422869.

5: Cordeiro MF, Goldberg I, Schiffman R, Bernstein P, Bejanian M. Efficacy of a
preservative-free formulation of fixed-combination bimatoprost and timolol
(Ganfort PF) in treatment-naïve patients vs previously treated patients. Clin
Ophthalmol. 2015 Aug 31;9:1605-11. doi: 10.2147/OPTH.S84163. eCollection 2015.
PubMed PMID: 26357461; PubMed Central PMCID: PMC4560512.

6: Maruyama Y, Ikeda Y, Mori K, Ueno M, Yoshikawa H, Kinoshita S. Comparison
between bimatoprost and latanoprost-timolol fixed combination for efficacy and
safety after switching patients from latanoprost. Clin Ophthalmol. 2015 Aug
7;9:1429-36. doi: 10.2147/OPTH.S87613. eCollection 2015. PubMed PMID: 26300624;
PubMed Central PMCID: PMC4535543.

7: Wirta D, Pariser DM, Yoelin SG, Arase S, McMichael A, Weng E, Mao C, Demos G,
Vandenburgh A. Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A
Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials. J Clin
Aesthet Dermatol. 2015 Jul;8(7):17-29. PubMed PMID: 26203317; PubMed Central
PMCID: PMC4509582.

8: Kook MS, Simonyi S, Sohn YH, Kim CY, Park KH. Bimatoprost 0.01 % for
previously treated patients with open-angle glaucoma or ocular hypertension in
the Korean clinical setting. Jpn J Ophthalmol. 2015 Sep;59(5):325-34. doi:
10.1007/s10384-015-0392-2. Epub 2015 Jul 23. PubMed PMID: 26202440.

9: Wirta D, Baumann L, Bruce S, Ahluwalia G, Weng E, Daniels S. Safety and
Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects. J Clin
Aesthet Dermatol. 2015 Apr;8(4):11-20. PubMed PMID: 26060513; PubMed Central
PMCID: PMC4456802.

10: Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
Plast Surg Nurs. 2015 Apr-Jun;35(2):82-91. doi: 10.1097/PSN.0000000000000097.
PubMed PMID: 26020474.

11: Schnober D, Hubatsch DA, Scherzer ML. Efficacy and safety of
fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from
bimatoprost 0.03%/timolol 0.5% combination therapy. Clin Ophthalmol. 2015 May
7;9:825-32. doi: 10.2147/OPTH.S80880. eCollection 2015. PubMed PMID: 26005326;
PubMed Central PMCID: PMC4428365.

12: Fang Y, Ling Z, Sun X. Fixed-combination treatments for intraocular
hypertension in Chinese patients - focus on bimatoprost-timolol. Drug Des Devel
Ther. 2015 May 13;9:2617-25. doi: 10.2147/DDDT.S80338. eCollection 2015. Review.
PubMed PMID: 25999695; PubMed Central PMCID: PMC4435054.

13: Sarnoff DS, Gotkin RH. Bimatoprost-induced chemical blepharoplasty. J Drugs
Dermatol. 2015 May;14(5):472-7. PubMed PMID: 25942665.

14: Jha AK, Sinha R, Prasad S, Nandan N. Bimatoprost in periorbital vitiligo: a
ray of hope or dilemma. J Eur Acad Dermatol Venereol. 2015 May 4. doi:
10.1111/jdv.13176. [Epub ahead of print] PubMed PMID: 25941113.

15: Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus Mometasone
Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study. Dermatology.
2015;230(4):308-13. doi: 10.1159/000371416. Epub 2015 Mar 4. PubMed PMID:

16: Rossetti L, Sacchi M, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M,
Boehm A, Vorwerk C, Goldblum D, Fogagnolo P. Comparison of the effects of
bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood
and ocular perfusion pressures: the results of a randomized trial. BMC
Ophthalmol. 2015 Jan 22;15:7. doi: 10.1186/1471-2415-15-7. PubMed PMID: 25613811;
PubMed Central PMCID: PMC4320581.

17: Prévost S, Thai K, Schützenmeister N, Coulthard G, Erb W, Aggarwal VK.
Synthesis of prostaglandin analogues, latanoprost and bimatoprost, using
organocatalysis via a key bicyclic enal intermediate. Org Lett. 2015 Feb
6;17(3):504-7. doi: 10.1021/ol503520f. Epub 2015 Jan 12. PubMed PMID: 25582321.

18: Natt NK, Gupta A, Singh G, Singh T. A pharmacoeconomic analysis to determine
the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine
0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Indian J Ophthalmol. 2014 Dec;62(12):1136-40. doi: 10.4103/0301-4738.149134.
PubMed PMID: 25579357; PubMed Central PMCID: PMC4313493.

19: García-López A, Paczka JA, Jiménez-Román J, Hartleben C. Efficacy and
tolerability of fixed-combination bimatoprost/timolol versus fixed-combination
dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or
ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol.
2014 Dec 19;14:161. doi: 10.1186/1471-2415-14-161. PubMed PMID: 25527295; PubMed
Central PMCID: PMC4298061.

20: Park KH, Simonyi S, Kim CY, Sohn YH, Kook MS. Bimatoprost 0.01% in
treatment-naïve patients with open-angle glaucoma or ocular hypertension: an
observational study in the Korean clinical setting. BMC Ophthalmol. 2014 Dec
17;14:160. doi: 10.1186/1471-2415-14-160. PubMed PMID: 25519810; PubMed Central
PMCID: PMC4289567.